<DOC>
	<DOCNO>NCT00003326</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness paclitaxel treat patient metastatic , recurrent , unresectable cancer esophagus .</brief_summary>
	<brief_title>Paclitaxel Treating Patients With Metastatic , Recurrent , Unresectable Cancer Esophagus</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate paclitaxel administer weekly one hour infusion patient metastatic , locally recurrent , unresectable squamous cell carcinoma adenocarcinoma esophagus . II . Evaluate safety paclitaxel patient population . III . Assess overall survival quality life patient . OUTLINE : This open label , multicenter study . Patients receive intravenous paclitaxel 1 hour weekly . Each course consist four week . Patients receive treatment disease progression unacceptable toxic effect observe . Patient response assess every 2 course first year every 3 month subsequent year . Quality life assess prior treatment , prior course 6 course , every 2 course . Patients follow every 3 month death . PROJECTED ACCRUAL : A total 100 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic , locally recurrent , unresectable squamous cell carcinoma adenocarcinoma esophagus The bulk tumor must involve esophagus gastroesophageal ( GE ) junction ( tumor extend GE junction proximal stomach ) Gastric cancer minor GE junction distal esophagus involvement eligible Measurable evaluable disease No prior treatment metastatic disease No brain metastases No osseous metastasis site disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2 mg/dL AST ALT great 2 time upper limit normal ( ULN ) Renal : Creatinine great 2 time ULN Calcium great 12 mg/dL Cardiovascular : No New York Heart Association class III/IV heart disease No myocardial infarction within 6 month study No congestive heart failure No unstable angina No clinically significant pericardial effusion arrhythmia Neurologic : No concurrent peripheral neuropathy great grade 1 Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active serious infection medical illness No history hypersensitivity drug contain Cremophor ( teniposide , cyclosporine , vitamin K ) No invasive malignancy within 5 year , except : Curatively treat basal squamous cell carcinoma skin Curatively treat carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy within 4 week study No concurrent immunotherapy Chemotherapy : No 1 prior chemotherapy regimen chemotherapy/radiation therapy give neoadjuvant adjuvant setting No prior chemotherapy within 4 week study No concurrent chemotherapy Endocrine therapy : No prior hormonal therapy within 4 week study Concurrent megestrol ( Megace ) allow No concurrent hormonal therapy Radiotherapy : No prior radiotherapy within 4 week study No prior radiation great 30 % bone marrow No 1 prior chemotherapy/radiation therapy regimen give neoadjuvant adjuvant set No concurrent radiotherapy Surgery : No prior surgery within 2 week study Other : No prior parenteral antibiotic within 1 week study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2001</verification_date>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>